Risk Factors for Recurrence and Unfavorable Prognosis in Patients with Stage I Non-small Cell Lung Cancer and a Tumor Diameter of 20 mm or Less
Open Access
- 1 September 2007
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 2 (9), 808-812
- https://doi.org/10.1097/jto.0b013e31814617c7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- RETRACTED: 100 years of lung cancerRespiratory Medicine, 2006
- Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trialThe Lancet Oncology, 2006
- What are the clinical features of lung cancer before the diagnosis is made? A population based case-control studyThorax, 2005
- Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Bronchioloalveolar Carcinoma of the Lung 3 Centimeters or Less in Diameter: A Prognostic AssessmentThe Annals of Thoracic Surgery, 2004
- A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the LungNew England Journal of Medicine, 2004
- Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung CancerNew England Journal of Medicine, 2004
- Tumor Size Predicts Survival Within Stage IA Non-Small Cell Lung Cancer *Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2003
- Revisions in the International System for Staging Lung CancerSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1997
- Survival in early-stage non-small cell lung cancerThe Annals of Thoracic Surgery, 1995